219 related articles for article (PubMed ID: 28447314)
1. Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
Nordstrand A; Bergström SH; Thysell E; Bovinder-Ylitalo E; Lerner UH; Widmark A; Bergh A; Wikström P
Clin Exp Metastasis; 2017 Apr; 34(3-4):261-271. PubMed ID: 28447314
[TBL] [Abstract][Full Text] [Related]
2. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
Tsushima H; Morimoto S; Fujishiro M; Yoshida Y; Hayakawa K; Hirai T; Miyashita T; Ikeda K; Yamaji K; Takamori K; Takasaki Y; Sekigawa I; Tamura N
Autoimmunity; 2017 Aug; 50(5):329-335. PubMed ID: 28682648
[TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H
Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284
[TBL] [Abstract][Full Text] [Related]
4. Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
Wu W; Ma J; Shao N; Shi Y; Liu R; Li W; Lin Y; Wang S
PLoS One; 2017; 12(1):e0169229. PubMed ID: 28046018
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
Tanno B; Mancini C; Vitali R; Mancuso M; McDowell HP; Dominici C; Raschellà G
Clin Cancer Res; 2006 Nov; 12(22):6772-80. PubMed ID: 17121898
[TBL] [Abstract][Full Text] [Related]
6. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
[TBL] [Abstract][Full Text] [Related]
7. The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
Maiso P; Ocio EM; Garayoa M; Montero JC; Hofmann F; García-Echeverría C; Zimmermann J; Pandiella A; San Miguel JF
Br J Haematol; 2008 May; 141(4):470-82. PubMed ID: 18341634
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
Isebaert SF; Swinnen JV; McBride WH; Haustermans KM
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):239-47. PubMed ID: 21816290
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
10. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
11. Dual treatments targeting IGF-1R, PI3K, mTORC or MEK synergize to inhibit cell growth, induce apoptosis, and arrest cell cycle at G1 phase in MDA-MB-231 cell line.
Ayub A; Yip WK; Seow HF
Biomed Pharmacother; 2015 Oct; 75():40-50. PubMed ID: 26463630
[TBL] [Abstract][Full Text] [Related]
12. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
Tazzari PL; Tabellini G; Bortul R; Papa V; Evangelisti C; Grafone T; Martinelli G; McCubrey JA; Martelli AM
Leukemia; 2007 May; 21(5):886-96. PubMed ID: 17361225
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
[TBL] [Abstract][Full Text] [Related]
15. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
Whitson BA; Jacobson BA; Frizelle S; Patel MR; Yee D; Maddaus MA; Kratzke RA
Ann Thorac Surg; 2006 Sep; 82(3):996-1001; discussion 1001-2. PubMed ID: 16928523
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
Ekyalongo RC; Mukohara T; Kataoka Y; Funakoshi Y; Tomioka H; Kiyota N; Fujiwara Y; Minami H
Invest New Drugs; 2013 Apr; 31(2):293-303. PubMed ID: 22828916
[TBL] [Abstract][Full Text] [Related]
17. SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer.
Iglesias-Gato D; Chuan YC; Wikström P; Augsten S; Jiang N; Niu Y; Seipel A; Danneman D; Vermeij M; Fernandez-Perez L; Jenster G; Egevad L; Norstedt G; Flores-Morales A
Carcinogenesis; 2014 Jan; 35(1):24-33. PubMed ID: 24031028
[TBL] [Abstract][Full Text] [Related]
18. Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
Wolf S; Lorenz J; Mössner J; Wiedmann M
World J Gastroenterol; 2010 Jan; 16(2):156-66. PubMed ID: 20066734
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.
Takayama K; Inoue T; Narita S; Maita S; Huang M; Numakura K; Tsuruta H; Saito M; Maeno A; Satoh S; Tsuchiya N; Habuchi T
Cancer Lett; 2017 Jul; 397():103-110. PubMed ID: 28373003
[TBL] [Abstract][Full Text] [Related]
20. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]